Recombinant antibodies having dual specificity for gangliosides and use thereof
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Dec 27, 2016
Grant Date -
Apr 2, 2015
app pub date -
Feb 21, 2013
filing date -
Mar 1, 2012
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention relates to new monoclonal antibodies and fragments of these antibodies, which have dual specificity and high affinity for N-acetyl GM3 and N-glycolyl GM3 and do not recognize other gangliosides. In another aspect, the present invention relates to the use of these antibodies and their fragments in the therapy of tumors characterized by a significant expression of any of the two antigens recognized by these antibodies, or a mixed expression of both antigens. Likewise, the invention relates to the use of these antibodies in the diagnosis of tumors expressing at least one of the two variants of the GM3 ganglioside.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully